semaglutide bs tirzepatide 10 and 15 mg versus 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison - Hankosky - 2025 - Diabetes, Obesity and Metabolism Efficacy of tirzepatide 5, 10

Semaglutide belongs to the GLP-1 receptor agonist class of medicines, which help lower blood sugar by stimulating insulin release, suppressing glucagon secretion, slowing gastric emptying, and reducing appetite

This medication works by targeting areas of the brain that regulate appetite and caloric intake, making it easier for you to manage your weight effectively

At present, the evidence supports vigilance, not blanket avoidance, while further studies work to determine whether the association reflects true causality or confounding

In SELECT, 16.6% of patients on semaglutide stopped the drug because of adverse events, against 8.2% on placebo, mostly gastrointestinal. In the meta-analysis, GI disorders were 63% more common with GLP-1 receptor agonists, gallbladder disorders 26% more common. Most patients tolerate them well